[Cullinan Therapeutics Unveils Interim REZILIENT3 Trial Data for NSCLC at IASLC 2026]
(RTTNews) – Cullinan Therapeutics Inc. (CGEM), a clinical‑stage biopharma firm developing next‑generation disease‑modifying T cell engagers for autoimmune disorders and cancer, disclosed findings from the anticipated interim analysis of its Phase 3 REZILIENT3 trial.
The REZILIENT3 trial tests Zipalertinib combined with chemotherapy for first‑line therapy in patients with EGFR exon 20 insertion‑positive nonsmall‑cell lung cancer (NSCLC). Key data will be presented at Presidential Symposium 2 during the International Association for the Study of Lung Cancer’s (IASLC) 2026 World Conference on Lung Cancer in Seoul, South Korea, scheduled for 13 September 2026.
At the interim analysis the trial achieved its primary endpoint—progression‑free survival—a pivotal milestone for patients with this rare exon 20 insertion mutation–driven NSCLC cohort.
Following the presentation, Cullinan will hold a virtual analyst and investor briefing on 14 September 2026 at 08:00 ET, featuring CEO Nadim Ahmed and CMO Jeffrey Jones, MD, MBA, who will discuss trial outcomes and the company’s pipeline roadmap.
Zipalertinib is an oral, selective EGFR inhibitor that targets exon 20 insertion mutations while preserving wild‑type EGFR, seeking to boost efficacy and reduce adverse effects versus current treatments.
The company reported Q2 2026 cash and liquidity of $356.0 million, ending the quarter with sufficient resources to sustain operations through 2029 under its current operating plan.
Over the past twelve months CGEM’s share price has ranged from $5.68 to $23.19, closing at $21.00 on Thursday—the day saw a 1.45 % decline.
Also Read
- Zeefman’s Analysis Reveals Four Pivots in Burnham’s Governing Blueprint
- Herzog Honors 9/11 Victims on 25th Anniversary at Jerusalem Memorial
- Ukraine says Russia fired 160 drones overnight, killing at least one and wounding dozens
- UK Commits to Fleet of Zero-Emission Trains to Accelerate Northern Rail Services
